Study guide

4.1 Established Guidelines for Care & Categories of Evidence

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

4.1 Established Guidelines for Care & Categories of Evidence

Key Takeaways Explain This Topic AI

NCCN category 1 requires high-level evidence with uniform panel consensus; category 2A requires lower-level evidence with uniform consensus; category 2B lower-level evidence with panel consensus only; and category 3 signals major disagreement.

The great majority of NCCN recommendations are category 2A, so 'category 2A' means standard of care rather than weak evidence.

USPSTF grades A and B indicate net benefit and trigger coverage without cost sharing under the Affordable Care Act, C indicates selective offering, D recommends against, and I signals insufficient evidence.

When guidelines conflict, compare publication date, scope, funding, and the population studied, and prefer the most recent guidance from the body with direct jurisdiction over the question.

Off-guideline treatment is defensible when documented as a deliberate, patient-specific decision that names the guideline, the reason for deviation, the alternatives discussed, and the patient's informed agreement.

Last updated: August 2026

4.1 Established Guidelines for Care & Categories of Evidence

Blueprint focus: ONCC Domain I.C.1 — Established guidelines for care. Exam items test whether you know which body owns which question, what an evidence category actually means, and what to do when two respected guidelines disagree.

Which Body Owns Which Question

Organization Scope Output

NCCN (National Comprehensive Cancer Network) Disease-specific treatment algorithms plus supportive care, survivorship, genetic/familial risk, and age-related considerations Clinical Practice Guidelines in Oncology, updated continuously, with categories of evidence and consensus

ASCO (American Society of Clinical Oncology) Focused clinical questions, especially supportive care, survivorship, and biomarker use Systematic-review-based guidelines with explicit strength of recommendation and quality of evidence

ONS (Oncology Nursing Society) Nursing-sensitive symptom interventions and safe practice standards Putting Evidence Into Practice resources, chemotherapy and immunotherapy administration standards

USPSTF Primary prevention and screening in asymptomatic people Letter-graded recommendation statements that determine ACA coverage

ASTCT / FACT Cell therapy and transplantation practice and accreditation Consensus grading (for example, ASTCT CRS/ICANS grading) and accreditation standards

  • IDSA / MASCC Infection and supportive care Febrile neutropenia management and antiemetic guidance
  • AJCC / WHO Staging and classification TNM staging manuals and tumor classification

The practical rule: for what treatment to give , start with NCCN. For how to manage a specific toxicity or supportive-care question , ASCO and ONS are usually more granular. For whether to screen an asymptomatic person , USPSTF sets the coverage-relevant standard while NCCN often recommends more intensive screening.

NCCN Categories of Evidence and Consensus

These four categories are among the most frequently misread items in oncology practice.

  • Category Level of evidence Degree of panel consensus Meaning in practice
  • 1 High (typically randomized phase III data) Uniform Strongest recommendation NCCN issues
  • 2A Lower-level evidence Uniform Appropriate; this is standard of care
  • 2B Lower-level evidence Consensus, but not uniform Reasonable; other options may be equally acceptable
  • 3 Any level Major disagreement among panel members Use only with explicit justification

The trap: candidates read "category 2A" as weak. It is not. The overwhelming majority of NCCN recommendations are category 2A, because randomized data do not exist for most specific clinical situations. Category 2A means the panel unanimously agrees the intervention is appropriate.

NCCN separately marks preferred , other recommended , and useful in certain circumstances interventions, which addresses relative position among equally acceptable options rather than evidence strength.

ASCO Guideline Grading

ASCO reports two things for each recommendation:

Strength of recommendation — strong, moderate, or weak.

Quality of evidence — high, intermediate, low, or insufficient.

A recommendation can be strong despite low-quality evidence when the balance of benefit and harm is lopsided, which is exactly the situation in much of supportive care. Duloxetine for painful chemotherapy-induced peripheral neuropathy and prophylactic antiemetics for high-emetogenic regimens are examples where clinical certainty exceeds what the trial base alone would suggest.

USPSTF Letter Grades

  • Grade Meaning Practice implication
  • A High certainty of substantial net benefit Offer or provide; covered without cost sharing under the ACA

B High certainty of moderate benefit, or moderate certainty of moderate-to-substantial benefit Offer or provide; also covered without cost sharing

C Small net benefit Offer selectively based on individual judgment and preference — this is the shared-decision-making grade

  • D No net benefit or harms outweigh benefit Recommend against
  • I Insufficient evidence Evidence cannot support a recommendation either way; explain the uncertainty

Prostate-specific antigen screening in men aged 55 to 69 is grade C , which is why it must be framed as an individualized conversation rather than a routine order. Grade A and B recommendations carry direct financial consequences for patients because they trigger first-dollar coverage.

Resolving Conflicting Guidelines

Guidelines routinely disagree, and the exam will present a scenario where they do. Work through five questions.

How current is each? Prefer the most recently updated guidance. NCCN updates continuously; USPSTF statements can be several years old between cycles.

Whose question is it? A screening question belongs to USPSTF and NCCN; a chemotherapy-toxicity question belongs to ASCO and ONS.

What population was studied? A guideline derived from average-risk adults does not govern a BRCA1 carrier.

What is the intended purpose? USPSTF explicitly weighs population-level net benefit including overdiagnosis and cost; NCCN weighs maximum individual detection. That difference explains most screening disagreements — for example, biennial mammography from age 40 to 74 (USPSTF) versus annual mammography from age 40 (NCCN).

Who wrote it and with what funding? Prefer guidance from the body with direct jurisdiction and transparent conflict-of-interest management over a manufacturer-sponsored summary.

When the disagreement genuinely cannot be resolved on those grounds, name both options to the patient and document a shared decision.

When Off-Guideline Care Is Appropriate

Guidelines describe populations; patients are individuals. Deviation is legitimate for comorbidity, organ dysfunction, drug interaction, patient goals, resource availability, or a documented allergy. It becomes indefensible when it is undocumented or unexamined.

A defensible off-guideline note states:

  • the guideline recommendation that would otherwise apply,
  • the specific patient factor that makes it unsuitable,
  • the alternatives considered,
  • the discussion held with the patient and their agreement, and

the monitoring plan that compensates for the deviation.

Guideline Fluency as a Quality Measure

Guideline concordance is itself a measured quality metric. ASCO's Quality Oncology Practice Initiative audits documentation of stage before treatment, biomarker testing before targeted therapy, antiemetic concordance, and timely palliative care referral. The Commission on Cancer accreditation standards likewise audit guideline-concordant care. Practical fluency therefore means knowing not only what the guideline says but where the practice's own performance is being counted.

Loading diagram... Choosing and Applying the Right Guideline